Cargando…

The effect of tenofovir on renal function in HIV-positive pregnant women

INTRODUCTION: Tenofovir is a commonly used component of antiretroviral therapy (ART) to reduce vertical transmission of HIV. Although systematic review of tenofovir use in pregnancy concluded it to be low risk for foetal abnormalities [1], data is limited on its impact on renal function in pregnant...

Descripción completa

Detalles Bibliográficos
Autores principales: Flanagan, Stuart, Barnes, Lynne, Anderson, Jane, Barber, Tristan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225428/
https://www.ncbi.nlm.nih.gov/pubmed/25397444
http://dx.doi.org/10.7448/IAS.17.4.19694
_version_ 1782343505041948672
author Flanagan, Stuart
Barnes, Lynne
Anderson, Jane
Barber, Tristan
author_facet Flanagan, Stuart
Barnes, Lynne
Anderson, Jane
Barber, Tristan
author_sort Flanagan, Stuart
collection PubMed
description INTRODUCTION: Tenofovir is a commonly used component of antiretroviral therapy (ART) to reduce vertical transmission of HIV. Although systematic review of tenofovir use in pregnancy concluded it to be low risk for foetal abnormalities [1], data is limited on its impact on renal function in pregnant women. A recent South African study [2] concluded that renal dysfunction in HIV-infected pregnant women is significantly less common than in other HIV-infected adults, however there is currently no UK data. We aimed to investigate the effect of tenofovir on renal function in HIV-1 positive pregnant women in a UK clinic. METHODS: We retrospectively analyzed data on renal function in pregnancy from a cohort of women attending a busy inner city London antenatal clinic. All women were screened for renal function throughout pregnancy via serum creatinine and estimated glomerular filtration rate (eGFR) calculated using modification of diet in renal disease (MDRD) and corrected for ethnicity. RESULTS: Ninety-seven HIV-1 positive women were registered at Homerton Hospital antenatal service of a total of 105 pregnancies between January 2010 and September 2013. Tenofovir was prescribed in 71/105 pregnancies (67.6%). Of the 71 pregnancies, 41 were prescribed tenofovir pre-conception (57.7%). Of the pregnant women who started tenofovir in pregnancy, 21/31 (67.7%) were initiated before week 24 of pregnancy, in line with British HIV association (BHIVA) guidelines [3]. There was no deterioration in median serum creatinine or decline in eGFR in women prescribed tenofovir during pregnancy. At six weeks after delivery, in the 42 women who continued tenofovir therapy and had eGFR measured, one woman had eGFR=60, all others eGFR >90 (Table 1). CONCLUSIONS: Consistent with current guidelines and experience, this study shows tenofovir did not cause decline in renal function in pregnancy in our cohort of HIV-1 positive women, whether started during pre-conception or during pregnancy. More evidence should be prospectively collected looking at effects of tenofovir on other measures of tubular renal function in pregnancy such as proteinuria and protein-creatinine ratio.
format Online
Article
Text
id pubmed-4225428
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-42254282014-11-13 The effect of tenofovir on renal function in HIV-positive pregnant women Flanagan, Stuart Barnes, Lynne Anderson, Jane Barber, Tristan J Int AIDS Soc Poster Sessions – Abstract P162 INTRODUCTION: Tenofovir is a commonly used component of antiretroviral therapy (ART) to reduce vertical transmission of HIV. Although systematic review of tenofovir use in pregnancy concluded it to be low risk for foetal abnormalities [1], data is limited on its impact on renal function in pregnant women. A recent South African study [2] concluded that renal dysfunction in HIV-infected pregnant women is significantly less common than in other HIV-infected adults, however there is currently no UK data. We aimed to investigate the effect of tenofovir on renal function in HIV-1 positive pregnant women in a UK clinic. METHODS: We retrospectively analyzed data on renal function in pregnancy from a cohort of women attending a busy inner city London antenatal clinic. All women were screened for renal function throughout pregnancy via serum creatinine and estimated glomerular filtration rate (eGFR) calculated using modification of diet in renal disease (MDRD) and corrected for ethnicity. RESULTS: Ninety-seven HIV-1 positive women were registered at Homerton Hospital antenatal service of a total of 105 pregnancies between January 2010 and September 2013. Tenofovir was prescribed in 71/105 pregnancies (67.6%). Of the 71 pregnancies, 41 were prescribed tenofovir pre-conception (57.7%). Of the pregnant women who started tenofovir in pregnancy, 21/31 (67.7%) were initiated before week 24 of pregnancy, in line with British HIV association (BHIVA) guidelines [3]. There was no deterioration in median serum creatinine or decline in eGFR in women prescribed tenofovir during pregnancy. At six weeks after delivery, in the 42 women who continued tenofovir therapy and had eGFR measured, one woman had eGFR=60, all others eGFR >90 (Table 1). CONCLUSIONS: Consistent with current guidelines and experience, this study shows tenofovir did not cause decline in renal function in pregnancy in our cohort of HIV-1 positive women, whether started during pre-conception or during pregnancy. More evidence should be prospectively collected looking at effects of tenofovir on other measures of tubular renal function in pregnancy such as proteinuria and protein-creatinine ratio. International AIDS Society 2014-11-02 /pmc/articles/PMC4225428/ /pubmed/25397444 http://dx.doi.org/10.7448/IAS.17.4.19694 Text en © 2014 Flanagan S et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Sessions – Abstract P162
Flanagan, Stuart
Barnes, Lynne
Anderson, Jane
Barber, Tristan
The effect of tenofovir on renal function in HIV-positive pregnant women
title The effect of tenofovir on renal function in HIV-positive pregnant women
title_full The effect of tenofovir on renal function in HIV-positive pregnant women
title_fullStr The effect of tenofovir on renal function in HIV-positive pregnant women
title_full_unstemmed The effect of tenofovir on renal function in HIV-positive pregnant women
title_short The effect of tenofovir on renal function in HIV-positive pregnant women
title_sort effect of tenofovir on renal function in hiv-positive pregnant women
topic Poster Sessions – Abstract P162
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225428/
https://www.ncbi.nlm.nih.gov/pubmed/25397444
http://dx.doi.org/10.7448/IAS.17.4.19694
work_keys_str_mv AT flanaganstuart theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen
AT barneslynne theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen
AT andersonjane theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen
AT barbertristan theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen
AT flanaganstuart effectoftenofovironrenalfunctioninhivpositivepregnantwomen
AT barneslynne effectoftenofovironrenalfunctioninhivpositivepregnantwomen
AT andersonjane effectoftenofovironrenalfunctioninhivpositivepregnantwomen
AT barbertristan effectoftenofovironrenalfunctioninhivpositivepregnantwomen